Adaptive Biotechnologies cites NCCN MRD guidance update for clonoSEQ
Adaptive Biotechnologies says updated NCCN Guidelines for multiple myeloma now include a dedicated framework for routine MRD assessment and specifically reference clonoSEQ as an FDA-cleared MRD assay, with 10-6 sensitivity now preferred.
Updated guidelines set out a dedicated framework for routine MRD assessment across the multiple myeloma patient journey. clonoSEQ was named as an FDA-cleared assay for MRD assessment, with 10-6 sensitivity now preferred. SEATTLE, Sept. 17, 2026 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation NAS…